AVEO-Biodesix Ink Deal - Analyst Blog


Shutterstock photo

AVEO Pharmaceuticals, Inc. ( AVEO ) entered into an agreement with Biodesix, Inc., a molecular diagnostics company, to develop and commercialize AVEO's oncology candidate, ficlatuzumab with Biodesix' companion diagnostic test, VeriStrat.

Ficlatuzumab works by inhibiting the hepatocyte growth factor HGF/c-Met pathway. AVEO has evaluated the candidate in two phase I studies and a phase II study so far. The phase II study evaluating ficlatuzumab in combination with AstraZeneca 's ( AZN ) Iressa (gefitinib) in treatment-naive non-small cell lung cancer (NSCLC) patients failed to meet its primary endpoint. Statistically significant improvement in overall response rate or progression-free survival (PFS) in treatment-naïve NSCLC patients was not observed by adding ficlatuzumab to Iressa.

However, an exploratory analysis using VeriStrat identified a patient sub-population that experienced a PFS and overall survival benefit after using ficlatuzumab plus Iressa. Thus, we are positive on AVEO's deal with Biodesix. We note that AVEO had been looking for a partner to pursue further development of ficlatuzumab for quite some time now.

Terms of the Deal

As per the terms of the deal, AVEO will initiate a proof-of-concept study later this year, evaluating ficlatuzumab in combination with Roche / Astellas Pharma, Inc. 's ( RHHBY / ALPMY ) Tarceva (erlotinib) in patients suffering from advanced NSCLC, selected using VeriStrat.

AVEO will receive up to $15 million funding from Biodesix for the study. The companies will share profits and development, regulatory and commercial costs for ficlatuzumab beyond the proof-of-concept study equally.

While Biodesix will be responsible for all development activities and sales and marketing costs for VeriStrat, AVEO will undertake the global commercialization responsibility of ficlatuzumab. Biodesix will record all revenues related to VeriStrat.

We note that several other companies are developing oncology candidates targeting the HGF/c-Met pathway.

AVEO carries a Zacks Rank #3 (Hold). Some better-ranked stocks include Astellas carrying a Zacks Rank #2 (Buy).


AVEO PHARMACEUT (AVEO): Free Stock Analysis Report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
More Headlines for: PFS , ALPMY , AVEO , AZN , RHHBY

More from Zacks.com




Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com